AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
78_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
1Group_NN
operating_GER
profit_NN
Before_IN
exceptional_JJ
Exceptional_JJ
2004_CD
items_NN
items_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Group_NN
turnover_NN
21,426_CD
21,426_CD
Operating_GER
costs_NN
Cost_NN
of_PIN
sales_NN
5,150_CD
5,150_CD
Distribution_NOMZ
costs_VPRT
177_CD
177_CD
Research_NN
and_PHC
development_NOMZ
3,803_CD
3,803_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
7,841_CD
7,841_CD
16,971_CD
16,971_CD
Other_JJ
operating_GER
income_NN
Royalties_NN
95_CD
95_CD
Other_JJ
income_NN
220 220 315 315_CD
Cost_NN
of_PIN
sales_NN
includes_VPRT
charges_NN
against_PIN
stock_NN
and_PHC
prepayments_NOMZ
in_PIN
respect_NN
of_PIN
Exanta_NN
and_PHC
Iressa_NN
totalling_VBG [WZPRES]
$_$
195m_CD
._.
Other_JJ
income_NN
includes_VPRT
gains_NN
arising_VBG [WZPRES]
from_PIN
disposals_NN
under_IN
ongoing_JJ
product_NN
and_PHC
investment_NOMZ
rationalisation_NOMZ
programs_NN
._.
Group_NN
operating_GER
profit_NN
4,770_CD
4,770_CD
Charges_NN
included_VBD
above_PLACE
for_PIN
depreciation_NOMZ
916_CD
916_CD
for_PIN
amortisation_NOMZ
311_CD
311_CD
for_PIN
impairment_NOMZ
41_CD
41_CD
Gross_NN
profit_NN
,_,
as_IN
defined_VBN
by_PIN
the_DT
Companies_NN
Act_NN
1985_CD
16,276_CD
16,276_CD
The_DT
charge_NN
for_PIN
impairment_NOMZ
arises_VPRT
from_PIN
writing_VBG [PUBV]
off_PIN
fixed_JJ
assets_NN
and_PHC
goodwill_NN
associated_VBN [WZPAST]
with_PIN
Iressa_NN
and_PHC
Exanta_NN
._.
